Navigation Links
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Date:1/8/2010

EAST BRUNSWICK, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

The Company announced that:

  • It has completed the reversion to the manufacturing processes used to manufacture its pegloticase active pharmaceutical ingredient (API) drug substance for the pivotal Phase 3 clinical trials which the Company had committed to pursue during the September 2009 Type "A" meeting as its plan to address the concerns raised by the Food and Drug Administration (FDA) in the July 31, 2009 complete response letter. Three consecutive batches of pegloticase API drug substance were manufactured in late October 2009 at the Company's third party contract manufacturer (CMO) and were then manufactured into final KRYSTEXXA drug product in November 2009. All batches were placed on stability testing by early December 2009. This manufacturing process reversion included the successful return to the PEGylation concentration utilized in the manufacture of pegloticase API for the pivotal replicate Phase 3 clinical trials.
  • The Company has received from its third party testing laboratories the majority of the in-process and final release analytical test results performed on the three consecutive batches of pegloticase API drug substance and final drug product. These analytical tests are necessary to validate these batches as being comparable to the drug product used in the Phase 3 clinical trials to establish the safety and effic
    '/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
3. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Savient Provides Update on Pegloticase BLA
6. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
7. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
8. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
9. Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc.
10. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
11. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  Shares of Aerie ... of their value yesterday following the results of the ... therapy, Rhopressa.  Despite the trial failing to meet its ... positive results may come from future studies. ... company overview, current pipeline, financial review, analyst summary, valuation, ...
(Date:4/30/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a ... reported financial results for the fourth quarter and fiscal ... and fiscal 2015 overview: , Revenues from continuing ... 33% over last year,s comparable quarter, and $202.6 million ... EPS of $0.50 for the fourth quarter, up 194% ...
(Date:4/30/2015)...  Accuray Incorporated (Nasdaq: ARAY ) announced ... MIM Software Inc. to further develop adaptive therapy ... product portfolios. The new software solution will ... Accuray,s second collaboration with MIM; the previous partnership ... treatment plan review capability, PlanTouch™. "Accuray ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... 23, 2012  (OTC: IFIX) Internal Fixation Systems today announced ... to market subtalar implants. These implants are used to ... both trauma conditions and arthritis.  IFS CEO, Stephen Dresnick, ... to fill out our portfolio, and gives us another ...
... Dana Taschner from the Los Angeles office of ... California,s best lawyers in the annual Southern California Super Lawyers ... Taschner has earned the Super Lawyers distinction. He holds ... The Best Lawyers in America , one of the leading guides ...
Cached Medicine Technology:Internal Fixation Systems Announces 510(k) Approval Granted by FDA for Subtalar Implants 2The Lanier Law Firm's Dana Taschner Recognized Among Southern California's Top Lawyers 2
(Date:5/2/2015)... Ticket Down has secured additional inventories of ... awaited event today, Saturday, May 2nd at the MGM Grand ... be able to secure tickets for both the actual fight ... fans have wanted for more than five years was finally ... will step inside the ring to fight Manny “Pac-Man” Pacquiao ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare announces ... new healthcare insurance to individuals and small businesses on ... is the nation’s first health insurance system built from ... Health Insurance was ZoomCare’s first such filing including rates ... review and regulation by the Oregon Insurance Division. Once ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
(Date:5/1/2015)... Hope For The Warriors® thanks All American ... Warriors® and military families. All American Ford presented two ... Warriors®, a national nonprofit dedicated to restoring a sense ... for our service members and our military families. , ... and matched small autograph fee from fans and presented ...
Breaking Medicine News(10 mins):Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... Wood was Mayo pioneer in aerospace medicineROCHESTER, Minn., March ... investigator credited with inventing the high-altitude pressure suit worn ... Minn. He was 97. "As both a physician and ... leadership to Mayo Clinic and scientific advancements to the ...
... for as Little as 35 CentsSAN CLEMENTE, Calif., March 23 ... forward to every morning. But at about three dollars ... nearly $1100 a year! In these tough economic times, ... reducing their latte consumption, but their calcium intake as well. ...
... La., March 23 Brain Gym(R) provides a simple ... and adults every day; difficulties with reading, writing, math, ... movement. Brain Gym(R) is based on the use ... process for Brain Balance, which can break through cognitive ...
... a debilitating fall. But a University of Illinois at Chicago ... by practicing the Chinese martial art of tai chi. , ... has studied and used tai chi as a way to ... she and a colleague have seen similar results in a ...
... WASHINGTON, March 23 Jesse Buchanan of Minden, NV, ... Tuesday, March 31, 2009 to meet with congressional leaders ... and more research toward a cure for epilepsy.Buchanan, 14, ... country participating in Kids Speak Up! , a ...
... Webcast to Discuss Key Trends Changing the Face of Global Pharma Marketing ... ... Manhattan Research, a global healthcare and pharmaceutical market research company, ... in emerging markets amidst the need for global best practices. The presentation ...
Cached Medicine News:Health News:Inventor of G-Suit Dies 2Health News:Inventor of G-Suit Dies 3Health News:Inventor of G-Suit Dies 4Health News:Boost Your Calcium Consumption - Have a Latte! 2Health News:Boost Your Calcium Consumption - Have a Latte! 3Health News:Learning Empowered by Movement; Brain Gym Exercises Wake Up Brain and Body 2Health News:Stroke survivors improve balance with tai chi 2Health News:Nevada Youth Shares Epilepsy Message On Capitol Hill 2Health News:Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3 2Health News:Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3 3
... VelaSmooth is the first and ... with the revolutionary elos combined ... Frequency and Infrared Light ... suction to reduce the appearance ...
... result of DEKA's new technology ... different methods capable of restoring,a ... treatment is designed to dramatically ... the combined action of a ...
... SilkPeel Dermalinfusion is the ... of deliver a topical dermaceutical ... effectively treats all skin types ... of dermatological conditions including hyperpigmentation, ...
... Novalis offers the Clareon to practices that ... treatment speed and efficacy. The versatility of ... a wide range of treatments that would ... never need to worry about obsolescence because ...
Medicine Products: